{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:07:38Z","timestamp":1765728458113},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.jacl.2013.01.006","type":"journal-article","created":{"date-parts":[[2013,2,4]],"date-time":"2013-02-04T19:25:52Z","timestamp":1360005952000},"page":"199-207","source":"Crossref","is-referenced-by-count":35,"title":["Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized double-blind (ORD) study"],"prefix":"10.1016","volume":"7","author":[{"given":"Ichiro","family":"Tatsuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentarou","family":"Kudou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ootake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2013.01.006_bib1","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0002-9149(96)00159-2","article-title":"Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men","volume":"77","author":"Assmann","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2013.01.006_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride levels is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol levels: a meta-analysis of population-based prospective studies","volume":"3","author":"Hokanson","year":"1996","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.jacl.2013.01.006_bib3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2013.01.006_bib4","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.01.006_bib5","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/01.CIR.0000038493.65177.94","article-title":"Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease","volume":"106","author":"Kris-Etherton","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.01.006_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5551\/jat.E554","article-title":"Goals of dyslipidemia management- executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese","volume":"14","author":"Teramoto","year":"2007","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2013.01.006_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0002-8703(03)00367-3","article-title":"Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS)","volume":"146","author":"Yokoyama","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2013.01.006_bib8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(89)90828-3","article-title":"Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART)","volume":"334","author":"Burr","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2013.01.006_bib9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"Dietary supplementation with n-3polyunsaturated fatty acids with vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2013.01.006_bib10","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1161\/01.CIR.0000014682.14181.F2","article-title":"Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction","volume":"105","author":"Marchioli","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.01.006_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ajcn\/84.1.5","article-title":"n-3 fatty acids from fish or fish-oil supplements, but not \u03b1-linoleic acid, benefit cardiovascular disease outcomes in primary- and secondary\u2014prevention studies: a systematic review","volume":"84","author":"Wang","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacl.2013.01.006_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCULATIONAHA.105.581355","article-title":"Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I","volume":"113","author":"Iso","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.01.006_bib13","first-page":"CD003177","article-title":"Omega 3 fatty acids for prevention and treatment of cardiovascular disease (review)","volume":"4","author":"Hooper","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacl.2013.01.006_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2217\/clp.09.34","article-title":"Omega-3 fatty acids for the treatment of elevated triglycerides","volume":"4","author":"Maki","year":"2009","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.jacl.2013.01.006_bib15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2146\/ajhp060164","article-title":"Prescription omega-3 fatty acids for the treatment of hyperetriglyceridemia","volume":"64","author":"McKenney","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jacl.2013.01.006_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.mol.0000236363.63840.16","article-title":"Why do omega-3 fatty acids lower serum triglycerides?","volume":"17","author":"Harris","year":"2006","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2013.01.006_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.atherosclerosis.2007.11.008","article-title":"Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives","volume":"197","author":"Harris","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2013.01.006_bib18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/14779072.6.3.391","article-title":"Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jacl.2013.01.006_bib19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00043798-199710000-00011","article-title":"Safety and efficacy of Omacor in severe hypertiglyceridemia","volume":"4","author":"Harris","year":"1997","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.jacl.2013.01.006_bib20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00044011-199815050-00004","article-title":"The effects of omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia","volume":"15","author":"Borthwick","year":"1998","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.jacl.2013.01.006_bib21","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1185\/03007991003645318","article-title":"Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients","volume":"26","author":"Bays","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2013.01.006_bib22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jacl.2009.08.001","article-title":"Effects of\u00a0prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia","volume":"3","author":"Davidson","year":"2009","journal-title":"J Clin Lipidol"},{"issue":"Suppl 1","key":"10.1016\/j.jacl.2013.01.006_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.amjcard.2005.12.026","article-title":"Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids","volume":"4","author":"Robinson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2013.01.006_bib24","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2013.01.006_bib25","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR 101) therapy in patients with very high triglyceride levels (from the Muticenter, plAcebo-controlled, Randomized, double-bliNd, 12-week study with an open-label Extension [MARINE] Trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287413000500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287413000500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T03:08:53Z","timestamp":1562641733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287413000500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1933287413000500"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2013.01.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}